



ASX RELEASE

Benitec accepted to present at the Australian Showcase: Amsterdam 2011 and at BioPartnering Europe

Tuesday 27 September 2011. Sydney, Australia. Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, has been accepted by Ausbiotech to present at the upcoming Australian Showcase: Amsterdam 2011 on Friday 7 October 2011 in Amsterdam, The Netherlands.

In announcing this on Friday, Ausbiotech described the opportunity thus: "Australian Showcase: Amsterdam 2011 will give European investors an overview of some of Australia's top life science companies. It is expected that over 50 investors, including venture capitalists, fund managers and investment bankers will be in attendance."

Benitec joins a select group of Australian biotech companies to be chosen to present in this forum. Benitec's Chief Executive Officer, Dr Peter French, will present Benitec's investment case.

Following the Amsterdam showcase, Dr French will travel to London where Benitec has also been selected to present at BioPartnering Europe on 11 October 2011.

"It is clear that Benitec's progress over the last 12 months in fund raising, in patents granted and in its preclinical programs is being recognized internationally, and this has contributed to our selection to present at these two European events", Dr French said.

In addition to the presentations, Benitec will also be involved in a number of individual meetings with industry attendees at BioPartnering Europe. The aim of the meetings will be to raise awareness within the biopharmaceutical industry of Benitec's technology in gene silencing for novel therapies for intractable human disease.

For further information

Dr Peter French
Chief Executive Officer
Tel: +61 (0)412 457 595

pfrench@benitec.com

About Benitec www.benitec.com

Benitec Limited is developing novel treatments for chronic and life-threatening conditions based on gene silencing using a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licences from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian Securities Exchange under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. Benitec aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house Benitec is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.